BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Scott N, Mohamed Z, Rwegasha J, Mbwambo J, Lemoine M, Hellard M. Upscaling prevention, testing and treatment to control hepatitis C as a public health threat in Dar es Salaam, Tanzania: A cost-effectiveness model. Int J Drug Policy. 2021;88:102634. [PMID: 31882272 DOI: 10.1016/j.drugpo.2019.102634] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Mafirakureva N, Stone J, Fraser H, Nzomukunda Y, Maina A, Thiong'o AW, Kizito KW, Mucara EWK, González Diaz CI, Musyoki H, Mundia B, Cherutich P, Nyakowa M, Lizcano J, Chhun N, Kurth A, Akiyama MJ, Waruiru W, Bhattacharjee P, Cleland C, Donchuk D, Luhmann N, Loarec A, Maman D, Walker J, Vickerman P. An intensive model of care for hepatitis C virus screening and treatment with direct-acting antivirals in people who inject drugs in Nairobi, Kenya: a model-based cost-effectiveness analysis. Addiction 2021. [PMID: 34184794 DOI: 10.1111/add.15630] [Reference Citation Analysis]
2 Chevaliez S, Wlassow M, Volant J, Roudot-Thoraval F, Bachelard A, Poiteau L, Trabut JB, Hézode C, Bourdel A, Dominguez S. Assessing Molecular Point-of-Care Testing and Dried Blood Spot for Hepatitis C Virus Screening in People Who Inject Drugs. Open Forum Infect Dis 2020;7:ofaa196. [PMID: 32617372 DOI: 10.1093/ofid/ofaa196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
3 Gountas I, Yiasemi I, Kyprianou E, Mina C, Georgiou C, Katsioloudes P, Kouroufexi A, Demetriou A, Xenofontos E, Nikolopoulos G. Planning the hepatitis C virus elimination in Cyprus: A modeling study. World J Gastroenterol 2021; 27(31): 5219-5231 [PMID: 34497446 DOI: 10.3748/wjg.v27.i31.5219] [Reference Citation Analysis]
4 Scott N, Win TM, Tidhar T, Htay H, Draper B, Aung PTZ, Xiao Y, Bowring A, Kuschel C, Shilton S, Kyi KP, Naing W, Aung KS, Hellard M. Hepatitis C elimination in Myanmar: Modelling the impact, cost, cost-effectiveness and economic benefits. Lancet Reg Health West Pac 2021;10:100129. [PMID: 34327345 DOI: 10.1016/j.lanwpc.2021.100129] [Reference Citation Analysis]
5 Fraser H, Stone J, Wisse E, Sambu V, Mfisi P, Duran IJ, Soriano MA, Walker JG, Makere N, Luhmann N, Kafura W, Nouvellet M, Ragi A, Mundia B, Vickerman P. Modelling the impact of HIV and HCV prevention and treatment interventions for people who inject drugs in Dar es Salaam, Tanzania. J Int AIDS Soc 2021;24:e25817. [PMID: 34661964 DOI: 10.1002/jia2.25817] [Reference Citation Analysis]